Stem Cell Therapy for Osteoarthritis - A Pipeline Analysis Report

This pipeline analysis report identifies Mesoblast, Regeneus, U.S. Stem Cell, Anterogen, Asterias Biotherapeutics as some of the key companies that are actively involved in the development of gene therapy for osteoarthritis patients. The report also presents a comprehensive analysis of the therapeutic assessment by therapy (monotherapy and combination therapy), by ROA (intra-articular, implant, and unspecified), and by stage and ROA (phase III, phase I/II, phase I and IND, and pre-clinical). This pipeline analysis report also provides an analysis of stem cell therapy for osteoarthritis based on indications such as osteoarthritis (unspecified), knee osteoarthritis, shoulder osteoarthritis, and hip osteoarthritis.

Overview of the pipeline analysis report on stem cell therapy for osteoarthritis

Osteoarthritis is one of the chronic conditions for joints which results in the breakdown and eventual loss of the cartilage of one or more joints. This can affect joints including hips, lower back, neck, small joints of the fingers, and the base of the thumb and big toe. With the increasing awareness of osteoarthritis, the rise in diagnosis rates, the growing older population, and the increasing cases of obesity, the osteoarthritis market will witness considerable growth in the coming years. According to Technavio’s pipeline analysis report, most of the molecules under investigation are currenty in the early stages of development. 

Our comparative analysis on the molecules in the pipeline for the stem cell therapy for osteoarthritis has identified that most of these molocules are in the pre-clinical, phase I, and phase II stages. GID Group’s GID SVF is in the phase III (pivotal) stage and the drug is based on GID technology. It is a monotherapy drug and can be administered through a single-use disposable device.

Key companies

This pipeline analysis report has identified fourteen companies that are actively involved in the development of stem cell therapy for osteoarthritis. Based on the companies’ revenue, this report has segregated the players into Tier 1, Tier 2, and Tier 3 companies. One of the major Tier 1 companies Mesoblast, is a leading player in the biotechnology industry and registered a revenue of almost USD 43 million in 2016.

The Tier 1 companies covered in the are –

• Mesoblast
• Regeneus
• U.S. Stem Cell
• Anterogen
• Asterias Biotherapeutics

Therapeutic assessment of stem cell therapy osteoarthritis pipeline molecules by therapy

• Monotherapy
• Combination therapy

Monotherapy drugs are used to treat a particular disease. Our analysts have identified that all the stem cell therapy osteoarthritis drugs that are currently in the pipeline are being developed as a monotherapy agent.

Analysis of the stem cell therapy osteoarthritis pipeline molecules by indication

• Osteoarthritis (unspecified)
• Knee osteoarthritis
• Shoulder osteoarthritis
• Hip osteoarthritis

Most of the companies currently involved in the stem cell therapy for osteoarthritis focus on the knee osteoarthritis segment. VivaTech International is the only company that si focusing on the shoulder, hip, and knee osteoarthritis.

Key questions answered in the report include

• What are the different stages of the pipeline molecules in investigation?
• What are the molecules in the various development stages in the stem cell therapy for osteoarthritis pipeline?
• Who are the key companies currently involved in the development of stem cell therapy for osteoarthritis?
• What are the inactive molecules in the stem cell therapy for osteoarthritis?
• What are the major regulatory authorities approving drugs in various regions?

Technavio also offers customization on reports based on specific client requirement.